Increased dopamine within the nigrostriatal pathway of patients with schizophrenia is proposed as a driver of psychosis [3]–[5] supported by the effectiveness of antipsychotics (which block dopamine D2 receptors) in diminishing symptoms of hallucinations and delusions [6]. This evidence concerns the gene DRD2 and schizophrenia.